The U.S. Food and Drug Administration (FDA) has approved SpringWorks Therapeutics' GOMEKLI (mirdametinib), SpringWorks’ MEK inhibitor, for the treatment of adult and pediatric patients...
The U.S. Food and Drug Administration (FDA) has approved AbbVie's EMBLAVEO (aztreonam and avibactam), as the first and only fixed-dose, intravenous, monobactam/β-lactamase inhibitor combination...
Bain Capital, a global private investment firm, has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma Corporation (Tanabe Pharma or MTPC) in a...